BRAIN AG Enlarges Management Board

18-Nov-2015 - Germany

Consistently driving the implementation of its industrialization strategy in the “BioIndustrial” division, BRAIN AG is growing its management team. On 1 November 2015, Mr Eric Marks (54) was named Chief Operating Officer (COO) of BRAIN AG. Chairmanship of the board (CEO) will be taken on by Dr Jürgen Eck, who has been with BRAIN and in its group of partners since 1994.

© Luise Böttcher, BRAIN Archive

Since 01 November 2015, Eric Marks has been part of the two-strong management board of BRAIN. On it, he holds the position of Chief Operating Officer (COO).

Eric Marks holds a university degree in business administration and has more than 25 years of experience in the industry, in particular with regard to the organisation and expansion of sales operations and the acquisition and support of key accounts with Gist-Brocades (NL) or Genencor (U.S.A.). Most recently, from 2006 to 2015, Mr Marks was employed at AB Enzymes based in Darmstadt, a wholly-owned subsidiary of Associated British Food plc. In his role as Global Sales Director and holding the position of “Vice President Global Sales and Business”, he was responsible for the global business organization of the company, which operates in the technical and food enzymes markets.

At BRAIN, Mr Marks will head BRAIN’s “BioIndustrial” business as COO and thus be responsible for the expansion of sales in the company’s subsidiaries and the marketing of BRAIN’s proprietary product pipeline. Even today, the “BioIndustrial” division accounts for more than half of the BRAIN group’s total operating performance.

Only in July of this year, BRAIN AG had made known that it was expanding its management team in view of the company’s growing operational units. Naming Eric Marks as the second chairman of the board augments this structure by an important capacity. As CEO, Dr Jürgen Eck now will be able to attend more closely to matters of strategy which concern the whole group. Since BRAIN currently is mostly financed by private equity, this also includes permanently being on the lookout for alternative possibilities regarding sound ways of financing growth in the future, e.g. through the capital market.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances